Tomoko Yamagishi Dressler Net Worth

The estimated Net Worth of Tomoko Yamagishi Dressler is at least $1.35 Million dollars as of 30 August 2024. Tomoko Dressler owns over 5,631 units of Evolus Inc stock worth over $1,257,866 and over the last few years Tomoko sold EOLS stock worth over $89,251.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Tomoko Dressler EOLS stock SEC Form 4 insiders trading

Tomoko has made over 1 trades of the Evolus Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Tomoko sold 5,631 units of EOLS stock worth $89,251 on 30 August 2024.

The largest trade Tomoko's ever made was selling 5,631 units of Evolus Inc stock on 30 August 2024 worth over $89,251. On average, Tomoko trades about 1,877 units every 0 days since 2023. As of 30 August 2024 Tomoko still owns at least 82,375 units of Evolus Inc stock.

You can see the complete history of Tomoko Dressler stock trades at the bottom of the page.

What's Tomoko Dressler's mailing address?

Tomoko's mailing address filed with the SEC is 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH, CA, 92660.

Insiders trading at Evolus Inc

Over the last 7 years, insiders at Evolus Inc have traded over $244,915,132 worth of Evolus Inc stock and bought 3,308,677 units worth $53,545,237 . The most active insiders traders include Biopharma, Inc. Aeon, Inc. Medytox, and 1 Llc Alphaeon. On average, Evolus Inc executives and independent directors trade stock every 25 days with the average trade being worth of $3,606,270. The most recent stock trade was executed by Sandra Beaver on 6 September 2024, trading 3,276 units of EOLS stock currently worth $49,074.

What does Evolus Inc do?

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.

Complete history of Tomoko Dressler stock trades at Evolus Inc

Evolus Inc executives and stock owners

Evolus Inc executives and other stock owners filed with the SEC include:

• Michael Jafar,
  Chief Commercial Officer
• David Moatazedi,
  President, Chief Executive Officer, Director
• Rui Avelar,
  Chief Medical Officer, Head of Research & Development
• David Moatazedi,
  Pres, CEO & Director
• Lauren Silvernail,
  Chief Financial Officer, Executive Vice President - Corporate Development
• Lauren P. Silvernail,
  CFO & Exec. VP of Corp. Devel.
• Dr. Rui Avelar Dip.SportMed, M.D., C.CFP,
  Chief Medical Officer and Head of R&D
• Karah Parschauer,
  Independent Director
• Peter Farrell,
  Independent Director
• Vikram Malik,
  Chairman of the Board
• David Gill,
  Independent Director
• Robert Hayman,
  Independent Director
• Simone Blank,
  Director
• Tram Bui,
  IR Contact Officer
• Jeff Plumer,
  General Counsel
• Jessica Novak,
  Sr. VP of HR
• Crystal Muilenburg,
  Chief Marketing Officer
• Kurt Knab,
  VP of Sales
• Jeffrey J. Plumer,
  Gen. Counsel
• David K. Erickson,
  VP of Investor Relations
• Biopharma, Inc. Aeon,
  
• Sandra Beaver,
  Chief Financial Officer
• Crystal Muilenburg,
  Chief Marketing Officer
• Albert G Iii White,
  Director
• Kristine Romine,
  Director
• Bosun Hau,
  Director
• 1 Llc Alphaeon,
  
• Brady Stewart,
  Director
• Tomoko Yamagishi Dressler,
  Chief Marketing Officer
• Inc. Medytox,